GeneDx Holdings Corp. (NASDAQ:WGS) is under scrutiny as the Rosen Law Firm investigates potential securities claims on behalf of its shareholders. The investigation follows allegations of misleading business practices, particularly concerning fraudulent schemes to exploit Medicaid and Medicare systems. These allegations have significantly impacted the company's stock, which saw a notable drop of $4.84 per share, or 6.7%, closing at $67.18 after a report by Grizzly Research.
The company's leadership has also been active in stock transactions. On July 9, 2025, CEO Stueland Katherine sold 3,220 shares of Class A Common Stock at $93 each, reducing her holdings to 1,720 shares. Similarly, CFO Feeley Kevin sold 5,278 shares at the same price, leaving him with 3,392 shares. These transactions were reported in Form 4 filings, which are publicly accessible on the SEC website.
Currently, WGS stock is priced at $82.56, reflecting a decrease of 5.01% or $4.35. The stock has shown volatility, with a daily range between $82.51 and $86.70. Over the past year, the stock has experienced significant fluctuations, reaching a high of $117.75 and a low of $25.32. This volatility may be concerning for investors, especially in light of the ongoing investigation.
GeneDx's market capitalization is approximately $2.36 billion, with a trading volume of 888,452 shares on the NASDAQ exchange. The company's financial health and future prospects are under the microscope as the Rosen Law Firm prepares a class action to recover investor losses. The firm's track record in securities class actions, including securing the largest settlement against a Chinese company, adds weight to the potential legal proceedings.
